Содержание

Содержание

Summary of findings
BackgroundПо подписке
3 подраздела
1. Description of the conditionПо подписке
2. Description of the intervention and how it might workПо подписке
3. Why it is important to do this reviewПо подписке
ObjectivesПо подписке
MethodsПо подписке
5 подразделов
1. Criteria for considering studies for this reviewПо подписке
  3 подраздела
  1. Types of studiesПо подписке
  2. Types of participantsПо подписке
  3. Types of interventionsПо подписке
2. Outcome measuresПо подписке
  2 подраздела
  1. Critical outcomesПо подписке
  2. Important outcomesПо подписке
3. Search methods for identification of studiesПо подписке
  2 подраздела
  1. Electronic searchesПо подписке
  2. Searching other resourcesПо подписке
4. Data collection and analysisПо подписке
  11 подразделов
  1. Selection of studiesПо подписке
  2. Data extraction and managementПо подписке
  3. Risk of bias assessment in included studiesПо подписке
  4. Measures of treatment effectПо подписке
  5. Unit of analysis issuesПо подписке
  6. Dealing with missing dataПо подписке
  7. Reporting bias assessmentПо подписке
  8. Synthesis methodsПо подписке
  9. Investigation of heterogeneity and subgroup analysisПо подписке
    1 подраздел
    Equity‐related assessmentПо подписке
  10. Sensitivity analysisПо подписке
  11. Certainty of the evidence assessmentПо подписке
5. Consumer involvementПо подписке
ResultsПо подписке
3 подраздела
1. Description of studiesПо подписке
  3 подраздела
  1. Results of the searchПо подписке
  2. Included studiesПо подписке
    7 подразделов
    Types of studiesПо подписке
    Types of participantsПо подписке
    Types of interventionsПо подписке
    Types of outcomesПо подписке
    Critical outcomesПо подписке
    Important outcomesПо подписке
    Adverse eventsПо подписке
  3. Excluded studiesПо подписке
    1 подраздел
    Studies awaiting classification and ongoing studiesПо подписке
2. Risk of bias in included studiesПо подписке
  7 подразделов
  1. Proportion of participants who were medication‐freeПо подписке
  2. Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
  3. Mean change in IOPПо подписке
  4. Mean change in the number of IOP‐lowering drops taken per dayПо подписке
  5. Mean change in health‐related quality of life (HRQoL), measured using any scaleПо подписке
  6. Proportion of participants who required further glaucoma surgery including laserПо подписке
  7. Adverse eventsПо подписке
3. Synthesis of resultsПо подписке
  5 подразделов
  1. Comparison 1: SC‐MIGS (MIGS that act on the Schlemm's canal) versus non‐MIGS surgical optionsПо подписке
    14 подразделов
    Critical outcomesПо подписке
    Proportion of participants medication‐freeПо подписке
    Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    Important outcomesПо подписке
    Mean change in IOPПо подписке
    Mean change in the number of IOP‐lowering drops taken per dayПо подписке
    Proportion of participants with IOP of 14, 18, 21 mmHg or less in the short termПо подписке
    Mean change in health‐related quality of life (HRQoL)По подписке
    Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    Adverse effectsПо подписке
    Proportion of participants with loss of visual acuityПо подписке
    Proportion of participants with bleedingПо подписке
    Proportion of participants with IOP spikesПо подписке
    Proportion of participants with endophthalmitisПо подписке
  2. Comparison 2: SC‐MIGS + phacoemulsification (SC‐MIGS) versus phacoemulsification only (phaco)По подписке
    14 подразделов
    Critical outcomesПо подписке
    Proportion of participants medication‐freeПо подписке
    Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    Important outcomesПо подписке
    Mean change in IOPПо подписке
    Mean change in the number of IOP‐lowering drops taken per dayПо подписке
    Proportion of participants with IOP of 18 mmHg or less in the short termПо подписке
    Mean change in health‐related quality of life (HRQoL)По подписке
    Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    Adverse effectsПо подписке
    Proportion of participants with loss of visual acuityПо подписке
    Proportion of participants with bleedingПо подписке
    Proportion of participants with IOP spikesПо подписке
    Proportion of participants with endophthalmitisПо подписке
  3. Comparison 3: SC‐MIGS (Schlemm's canal MIGS) versus MIGS that do not act on the Schlemm's canal (non‐SC‐MIGS)По подписке
    13 подразделов
    Critical outcomesПо подписке
    Proportion of participants medication‐free in the short term (6 to 18 months)По подписке
    Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    Important outcomesПо подписке
    Mean change in IOP in the short term (6 to 18 months)По подписке
    Mean change in the number of IOP‐lowering drops taken per day in the short term (6 to 18 months)По подписке
    Mean change in health‐related quality of life (HRQoL)По подписке
    Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    Adverse effectsПо подписке
    Proportion of participants with loss of visual acuityПо подписке
    Proportion of participants with bleedingПо подписке
    Proportion of participants with IOP spikesПо подписке
    Proportion of participants with endophthalmitisПо подписке
  4. Comparison 4: SC‐MIGS1 versus SC‐MIGS2По подписке
    14 подразделов
    Critical outcomesПо подписке
    Proportion of participants medication‐free in the short term (6 to 18 months)По подписке
    Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    Important outcomesПо подписке
    Mean change in IOP in the short term (6 to 18 months)По подписке
    Mean change in the number of IOP‐lowering drops taken per day in the short term (6 to 18 months)По подписке
    Proportion of participants who achieved an IOP of 15, 18, 21 mmHg or less in the short term (6 to 18 months)По подписке
    Mean change in health‐related quality of life (HRQoL)По подписке
    Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    Adverse effectsПо подписке
    Proportion of participants with loss of visual acuityПо подписке
    Proportion of participants with bleedingПо подписке
    Proportion of participants with IOP spikesПо подписке
    Proportion of participants with endophthalmitis at 12 monthsПо подписке
  5. Comparison 5: SC‐MIGS versus laserПо подписке
    12 подразделов
    Critical outcomesПо подписке
    Proportion of participants who were medication‐free in the medium term (18 to 36 months)По подписке
    Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    Important outcomesПо подписке
    Mean change in IOP in the medium term (18 to 24 months)По подписке
    Mean change in the number of IOP‐lowering drops taken per day in the medium term (18 to 24 months)По подписке
    Mean change in health‐related quality of life (HRQoL)По подписке
    Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    Adverse effectsПо подписке
    Proportion of participants with loss of visual acuityПо подписке
    Proportion of participants with bleedingПо подписке
    Proportion of participants with IOP spikesПо подписке
DiscussionПо подписке
4 подраздела
1. Summary of main resultsПо подписке
2. Limitations of the evidence included in the reviewПо подписке
3. Limitations of the review processesПо подписке
4. Agreements and disagreements with other studies or reviewsПо подписке
  2 подраздела
  1. MIGS versus non‐MIGSПо подписке
  2. MIGS with phaco versus phaco onlyПо подписке
Authors' conclusionsПо подписке
2 подраздела
1. Implications for practiceПо подписке
2. Implications for researchПо подписке
Supporting InformationПо подписке
Additional informationПо подписке
7 подразделов
1. AcknowledgementsПо подписке
  1 подраздел
  1. Editorial and peer‐reviewer contributionsПо подписке
2. Contributions of authorsПо подписке
3. Declarations of interestПо подписке
4. Sources of supportПо подписке
  2 подраздела
  1. Internal sourcesПо подписке
  2. External sourcesПо подписке
5. Registration and protocolПо подписке
6. Data, code and other materialsПо подписке
7. HistoryПо подписке
ReferencesПо подписке

Разделы с замком — в закрытой части: подписка Awamed+.

По подписке

Миниинвазивная хирургия трабекулярной сети при открытоугольной глаукоме

Авторы

21 июля 2026The Cochrane Database of Systematic Reviews Офтальмология Хирургия Источник

Minimally invasive trabecular meshwork surgery for open-angle glaucoma.

Summary of findings

Дальше — с подпиской Awamed+

Осталось ещё 963 абзаца. Подписка открывает материал целиком вместе с оригиналом, рисунками и файлами.

Подключить Awamed+Уже подписаны? Войти

Содержание

Summary of findings
BackgroundПо подписке
1. Description of the conditionПо подписке
2. Description of the intervention and how it might workПо подписке
3. Why it is important to do this reviewПо подписке
ObjectivesПо подписке
MethodsПо подписке
1. Criteria for considering studies for this reviewПо подписке
  1. Types of studiesПо подписке
  2. Types of participantsПо подписке
  3. Types of interventionsПо подписке
2. Outcome measuresПо подписке
  1. Critical outcomesПо подписке
  2. Important outcomesПо подписке
3. Search methods for identification of studiesПо подписке
  1. Electronic searchesПо подписке
  2. Searching other resourcesПо подписке
4. Data collection and analysisПо подписке
  1. Selection of studiesПо подписке
  2. Data extraction and managementПо подписке
  3. Risk of bias assessment in included studiesПо подписке
  4. Measures of treatment effectПо подписке
  5. Unit of analysis issuesПо подписке
  6. Dealing with missing dataПо подписке
  7. Reporting bias assessmentПо подписке
  8. Synthesis methodsПо подписке
  9. Investigation of heterogeneity and subgroup analysisПо подписке
    1. Equity‐related assessmentПо подписке
  10. Sensitivity analysisПо подписке
  11. Certainty of the evidence assessmentПо подписке
5. Consumer involvementПо подписке
ResultsПо подписке
1. Description of studiesПо подписке
  1. Results of the searchПо подписке
  2. Included studiesПо подписке
    1. Types of studiesПо подписке
    2. Types of participantsПо подписке
    3. Types of interventionsПо подписке
    4. Types of outcomesПо подписке
    5. Critical outcomesПо подписке
    6. Important outcomesПо подписке
    7. Adverse eventsПо подписке
  3. Excluded studiesПо подписке
    1. Studies awaiting classification and ongoing studiesПо подписке
2. Risk of bias in included studiesПо подписке
  1. Proportion of participants who were medication‐freeПо подписке
  2. Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
  3. Mean change in IOPПо подписке
  4. Mean change in the number of IOP‐lowering drops taken per dayПо подписке
  5. Mean change in health‐related quality of life (HRQoL), measured using any scaleПо подписке
  6. Proportion of participants who required further glaucoma surgery including laserПо подписке
  7. Adverse eventsПо подписке
3. Synthesis of resultsПо подписке
  1. Comparison 1: SC‐MIGS (MIGS that act on the Schlemm's canal) versus non‐MIGS surgical optionsПо подписке
    1. Critical outcomesПо подписке
    2. Proportion of participants medication‐freeПо подписке
    3. Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    4. Important outcomesПо подписке
    5. Mean change in IOPПо подписке
    6. Mean change in the number of IOP‐lowering drops taken per dayПо подписке
    7. Proportion of participants with IOP of 14, 18, 21 mmHg or less in the short termПо подписке
    8. Mean change in health‐related quality of life (HRQoL)По подписке
    9. Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    10. Adverse effectsПо подписке
    11. Proportion of participants with loss of visual acuityПо подписке
    12. Proportion of participants with bleedingПо подписке
    13. Proportion of participants with IOP spikesПо подписке
    14. Proportion of participants with endophthalmitisПо подписке
  2. Comparison 2: SC‐MIGS + phacoemulsification (SC‐MIGS) versus phacoemulsification only (phaco)По подписке
    1. Critical outcomesПо подписке
    2. Proportion of participants medication‐freeПо подписке
    3. Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    4. Important outcomesПо подписке
    5. Mean change in IOPПо подписке
    6. Mean change in the number of IOP‐lowering drops taken per dayПо подписке
    7. Proportion of participants with IOP of 18 mmHg or less in the short termПо подписке
    8. Mean change in health‐related quality of life (HRQoL)По подписке
    9. Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    10. Adverse effectsПо подписке
    11. Proportion of participants with loss of visual acuityПо подписке
    12. Proportion of participants with bleedingПо подписке
    13. Proportion of participants with IOP spikesПо подписке
    14. Proportion of participants with endophthalmitisПо подписке
  3. Comparison 3: SC‐MIGS (Schlemm's canal MIGS) versus MIGS that do not act on the Schlemm's canal (non‐SC‐MIGS)По подписке
    1. Critical outcomesПо подписке
    2. Proportion of participants medication‐free in the short term (6 to 18 months)По подписке
    3. Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    4. Important outcomesПо подписке
    5. Mean change in IOP in the short term (6 to 18 months)По подписке
    6. Mean change in the number of IOP‐lowering drops taken per day in the short term (6 to 18 months)По подписке
    7. Mean change in health‐related quality of life (HRQoL)По подписке
    8. Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    9. Adverse effectsПо подписке
    10. Proportion of participants with loss of visual acuityПо подписке
    11. Proportion of participants with bleedingПо подписке
    12. Proportion of participants with IOP spikesПо подписке
    13. Proportion of participants with endophthalmitisПо подписке
  4. Comparison 4: SC‐MIGS1 versus SC‐MIGS2По подписке
    1. Critical outcomesПо подписке
    2. Proportion of participants medication‐free in the short term (6 to 18 months)По подписке
    3. Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    4. Important outcomesПо подписке
    5. Mean change in IOP in the short term (6 to 18 months)По подписке
    6. Mean change in the number of IOP‐lowering drops taken per day in the short term (6 to 18 months)По подписке
    7. Proportion of participants who achieved an IOP of 15, 18, 21 mmHg or less in the short term (6 to 18 months)По подписке
    8. Mean change in health‐related quality of life (HRQoL)По подписке
    9. Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    10. Adverse effectsПо подписке
    11. Proportion of participants with loss of visual acuityПо подписке
    12. Proportion of participants with bleedingПо подписке
    13. Proportion of participants with IOP spikesПо подписке
    14. Proportion of participants with endophthalmitis at 12 monthsПо подписке
  5. Comparison 5: SC‐MIGS versus laserПо подписке
    1. Critical outcomesПо подписке
    2. Proportion of participants who were medication‐free in the medium term (18 to 36 months)По подписке
    3. Rate of visual field progression/proportion of participants whose visual field loss progressed in the follow‐up periodПо подписке
    4. Important outcomesПо подписке
    5. Mean change in IOP in the medium term (18 to 24 months)По подписке
    6. Mean change in the number of IOP‐lowering drops taken per day in the medium term (18 to 24 months)По подписке
    7. Mean change in health‐related quality of life (HRQoL)По подписке
    8. Proportion of participants who needed further glaucoma surgery, including laserПо подписке
    9. Adverse effectsПо подписке
    10. Proportion of participants with loss of visual acuityПо подписке
    11. Proportion of participants with bleedingПо подписке
    12. Proportion of participants with IOP spikesПо подписке
DiscussionПо подписке
1. Summary of main resultsПо подписке
2. Limitations of the evidence included in the reviewПо подписке
3. Limitations of the review processesПо подписке
4. Agreements and disagreements with other studies or reviewsПо подписке
  1. MIGS versus non‐MIGSПо подписке
  2. MIGS with phaco versus phaco onlyПо подписке
Authors' conclusionsПо подписке
1. Implications for practiceПо подписке
2. Implications for researchПо подписке
Supporting InformationПо подписке
Additional informationПо подписке
1. AcknowledgementsПо подписке
  1. Editorial and peer‐reviewer contributionsПо подписке
2. Contributions of authorsПо подписке
3. Declarations of interestПо подписке
4. Sources of supportПо подписке
  1. Internal sourcesПо подписке
  2. External sourcesПо подписке
5. Registration and protocolПо подписке
6. Data, code and other materialsПо подписке
7. HistoryПо подписке
ReferencesПо подписке